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INTRODUCTION
Urinary tract stone disease is the third most 
common urinary tract abnormality after urinary tract 
infections and prostate disorders. Without medical 
intervention and reliable follow-up, the recurrence 
1rate may reach 50% within 5 years.  The prevalence 
of urinary tract stones in the world is estimated with 
lifetime incidence of 10-15% with a recurrence rate 
of 10% in 1 year, 35% in 5 years and 50% in 10 
2years.  In Indonesia, urinary tract stone disease is still 
the largest number of patients in urology clinic with 
3the uncertain incidence.  At the Urology Depart-
ment, Dr. Soetomo Hospital Surabaya, urinary tract 
stone disease is second in number of cases only to 
4prostate disease, with 577 cases/year.
Urinary tract stone recurrence rate is high 
enough to cause certain problems in terms of health 
financing. In the United States, urinary tract stone 
disease raises problems in health budget, with cost 
52,1 billion dollars per year.  Lost work time, 
hospitalization and surgery in patients with kidney 
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6,7stones spend 5 billion U.S. dollars each year,  with 
8peak incidence in age group 20-50 years,  and the 
9ratio between men and women is 3 to 1.  This 
suggests that the disease often affects productive age 
group.
Until now the management of patients with 
kidney stones include conservative measures, 
medical, minimally invasive, ESWL and open 
surgery. Role of phytopharmaceuticals in the 
treatment of kidney stones is still under debate and 
has not been a gold standard. Kidney stones are 
complex, because the process of its formation is still 
uncertain. In addition to dietary modifications and 
adequate hydration, the use of phytopharmaceuticals 
continues to grow. Certain phytopharmaceuticals 
claim effectiveness in kidney stones and are widely 
distributed. However, the research and clinical 
publications about those drugs are still very limited. 
Kalkurenal is a phytopharmaceutical that claims to 
destroy kidney stones and it has been distributed in 
Indonesia for a long time. Many clinicians prescribe 
it. Renalof® is a new product in Indonesia that is 
effective to destroy calcium oxalate renal calculi. As 
known in the literature, approximately 80% of the 
10composition of the stone is calcium oxalate.  
Wibisono conducted a retrospective study on 154 
kidney stone patients in Dr. Soetomo Hospital 
Surabaya between 2007-2009 and the analysis 
results revealed 87,67% stones with calcium 
11oxalate.
Several studies have been conducted on 
Renalof®, including 1) A study by Dr. Med. 
Constantin Nitoiu, Romania in 2005 under the title 
"The treatment of renal lithiasis and microlithiasis 
with RENALOF® preparation", 2) Research by 
Professor Mayra, Havana in 2008, a Clinical trial 
entitled "Treatment of renal lithiasis with food 
supplement Renalof", 3) Research by Aties M, 
Cuban Institute of Nephrology in 2009 under the title 
"Double-blind randomized study: Efficacy and 
safety of Renalof® in the treatment of patient carrier 
of calcium oxalate renal lithiasis". Of the three 
studies, Renalof® is effective in kidney stones with a 
size less than 20 mm, and decline in the size of the 
stones had been seen in one month administration.
Metabolic risk factors also play a role in the 
formation of kidney stones such as hypercalciuria, 
hyperuricosuria, hyperoxaluria, hypocitraturia, low 
levels of magnesium and stone inhibitor deficiency. 
30-60% of nephrolithiasis patients were with 
12hypercalciuria and 15-20% with hyperuricosuria.
High recurrence rate also poses particular 
problems in terms of health financing. In the United 
States, urinary tract stone disease raises a problem in 
health budget, with a cost of 2,1 billion dollars per 
5year.  Lost work time, hospitalization and surgery in 
patients with kidney stones spend 5 billion U.S. 
6,7dollars each year,  while in Indonesia it is still not 
determined.
This study compared the stone-free rate of 
kidney stone patients with a size less than 20 mm 
after Renalof ® administration compared to Kalku-
renal ® and placebo for 1 month.
OBJECTIVE
Comparing the effectiveness of Renalof® in 
patients with kidney stones compared to Kalku-
renal® and placebo.
MATERIAL & METHOD
This study used double-blind prospective 
clinical study design conducted from January – 
March 2011 in Dr. Soetomo Hospital, Surabaya.
The samples in this study were randomly 
allocated into 3 groups, each group of 8 persons, 
namely group 1 (control group with placebo), group 
2 (group treated with Kalkurenal®) and group 3 
(group treated with Renalof®). All patients enrolled 
had a single kidney stone with largest diameter ≤ 20 
mm.
Furthermore, examination on the patient 
was done for the urinary profiles of calcium, uric 
acid, phosphate, urine pH and urine volume for 24 
hour, and then the serum measurements of calcium, 
uric acid, phosphate and stone analysis. Early 
imaging was performed, presenting as plain 
abdominal radiograph, renal ultrasonography and 
IVP. After undergoing treatment with placebo, 
Renalof® and Kalkurenal® for 4 weeks, we 
evaluated plain abdominal radiograph and renal 
ultrasound in week 4. The patients were examined 
for profiles of calcium, uric acid, phosphate and 
urine volume capacity of 24-hour collected urine and 
the profiles of calcium, uric acid, and phosphate in 
blood.
The analysis was descriptive and analytic. 
Comparison test was performed on three sample 
groups of using the paired Student t-test for 
comparing the three groups and the data were 
nominal. Testing of data homogeneity and normality 
of data using ANOVA and the Kolmogorov-Smirnov 
test and regression analysis were performed. 
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Statistical tests with commercial statistical software 
package.
RESULTS
Baseline demographic characteristics of the 
sample with enrolled samples of 30 patients and 38 
renal units are shown in table 1. There were 14 men 
and 16 women. Mean body mass index was 26,08 ± 
2,86; classified as overweight (BMI 25 to 29,9). 
Most of the stones were located in the right kidney, 
comprising 22 renal units (57,89%) and most of the 
Table 1. Demographic characteristics of the study.
Parameter Placebo Kalkurenal® Renalof®  
Total Patients (n) 9 8 13 
Total renal units (n) 10 9 19 
Male/Female (n) 5/4  4/4 5/8 
Age (mean ± SD) 50,56 ± 9,697 54,13 ± 10,02 45,31 ± 10,55 
IMT (mean  SD) 25,58  2,05 27,5  3,36 25,55  2,92 
Stone size (mean ± SD) 5,8 ± 1,93 8 ± 2,74 7,32 ± 2,83 
Stone surface size (mean ± SD) 0,22 ± 0,8 1,10 ± 1,92 3,98 ± 5,84 
Lateralization (n renal unit = 38)    
• Right kidney stone 6 (15,79%) 4 (10,53%) 12 (31,58%) 
• Left kidney stone 4 (10,53%) 5 (13,52) 7 (18,42%) 
Stone position (n renal unit = 38)    
• Upper pole 0 0 0 
• Middle pole 8 (21,05%) 7 (18,42) 8 (21,05%) 
• Lower pole 3 (7,89) 2 (5,26%) 10 (26,31%) 
Stone size in renal USG (n renal unit = 38)    
• = 5 mm 5 (13,56%) 1 (2,63%) 7 (18,42%) 
• 6-9 mm 4 (10,53%) 5 (13,16%) 8 (21,05%) 
• 10-20 mm 1 (2,63%) 2 (5,26%) 5 (13,16%) 
24-hour urine excretion    
• 24-hour calcium excretion (mean ± SD) mg 141,6 ± 60,65 175,69 ± 96,38 166,2 ± 68 
•24-houruric acidexpression(mean ±SD) mg 448,28 ±244,31 508,18 ±82 462,46 ±198,88
 
 
Table 2. Characteristics of sex, stone position, and location.
Categories Frequency Percentage
Sex Male 14 46,67 
 Female 16 53,33 
 Total 30 100 
Stone location Upper pole 0 0 
 Middle pole 23 60,53 
 Lower pole 15 39,47 
 Total 38 100 
Stone position Right kidney 22 57,89 
 Left kidney 16 42,11 
Total 38 100
stones position was at middle pole of the kidney, 
comprising 23 renal units (60,53%). Most were 
stones with a size of  6-9 mm (44,74%).
In Table 2 the most frequent stone location 
was at the center pole (60,53%) and lower pole 
(39,47%), and stones were more frequently observed 
in the right kidney than the left kidney (57,89% vs. 
42,11%).
The results of stone analysis showed that the 
calcium and oxalate were the most common 
components (33,48 + 8,87 vs. 38,78 + 16,67) 
followed by uric acid (12,78 + 12,50). The most 
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common type of stone was calcium oxalate (61,94 + 
21,04) followed by magnesium ammonium 
phosphate stones (23,33 + 24,82) and uric acid 
(13,40 + 14,12).
Table 3 shows the decline in blood calcium 
in the three treatment groups, whereas in Renalof® 
and Kalkurenal® groups there was a significant 
decrease (p = 0,015 and p = 0,045; p < 0,05).
Table 4 shows none of the three treatment 
groups had decreased significant of blood uric acid 
(p > 0,05), whereas in Table 5 none of the significant 
Table 3. Paired sample test of blood calcium profile at the early and end of week 4.
 Placebo Kalkurenal® Renalof® 
Mean 10,133 1,0875 0,507 
Standard Deviation  31,24 0,9627 0,820 
p 0,359 0,015 0,045
decrease in all three treatment groups (p > 0,05).
There was an increase in urinary excretion 
of uric acid in Kalkurenal® group (table 6), and a 
decrease in urinary excretion of uric acid in 
Renalof® group, but the differences did not seem 
significant (p > 0,05).
Apparently, there was a decrease in the 
surface area of the stones in all three treatment 
groups (Table 7), but there was a significant 
reduction in Renalof® group (p = 0,01; p < 0,05).
Table 4. Paired sample test of blood uric acid at the early and end of week 4.
 Placebo Kalkurenal® Renalof® 
Mean 0,469 0,4687 0,028 
Standard Deviation  1,163 1,1628 2,067 
p 0,292 0,292 0,962 
Table 5. Changes in 24-hour calcium excretion of at the start and end of week 4.
 
  Placebo Kalkurenal® Renalof® 
Groups
Early week 1 
End week 4 
Delta 
p
141,60 ± 60,64 
110,22 ± 28,93 
31,37 ± 76,95 
0,256
175,69 ± 96,36 
132,06 ± 75,02 
43,63 ± 61,64 
0,085
166,20 ± 68,00 
151,49 ± 163,63 
14,71 ± 169,13 
0,759
448,28 ± 244,31 
344,30 ± 83, 22 
103,92 ± 253,21 
0,253
508,19 ± 82,00 
656,92 ± 421,57 
148,74 ± 356,55 
0,277
462,46±198,87 
453,00 ±250,88 
9,46 ± 282,86 
0,906
 Placebo Kalkurenal® Renalof® 
Groups
  
Early week 1 
End week 4 
Delta 
p
Table 6. Changes in 24-hour uric acid excretion at the start and end of week 4.
Table 7. Paired sample test the surface area of the stones at the start and end of week 4.
 Placebo Kalkurenal® Renalof® 
Mean 
Standard Deviation  
p
0,388 
1,056 
0,334
4,30 
6,30 
0,095
6,46 
6,30 
0,01
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Table 8. Paired sample test on the mean size of the stone in USG at the start and end of week 4.
Placebo Kalkurenal® Renalof® 
Mean 0,100 0,111 1,210 
Standard Deviation 0,568 0,600 2,123 
p 0,591 0,594 0,023
Table 9. Differences in stone-free rate in placebo, Kalkurenal® and Renalof® at week 4 (n = 38).
  Placebo (n - 10) Kalkurenal® (n - 9) Renalof® (n - 19) 
Groups
Free stone incidence  
Free stone 1 (2,63%) 0 3 (7,89%) 
Residual stone 9 (23,68%) 9 (23,69%) 16 (42,11%) 
Total 10 (26,31%) 9 (23,69%) 19 (50%)
 
In Table 8 there is significant reduction in 
the size of the stones on Renalof® group (p = 0,023; 
p < 0,05).
DISCUSSION
In this study age distribution of the samples 
according to treatment groups was homogeneous (p 
= 0,159; p > 0,05), and age distribution of the sample 
revealed normal distribution (p = 0,963; p > 0,05). 
Profiles of calcium and uric acid in 24-hour urine in 
each treatment group showed no significant 
relationship (p = 0,870; p = 0,226; p > 0,05).
Sample were obtained from the youngest 
age of 30 years and the oldest 68 years (age range 30-
68 years). The mean age of the study sample was 
49,23 ± 10,5 years. From a total of 30 patients 
enrolled, 14 patients were male (46,67%) and 16 
were female (53,33%). According to age groups, 14 
patients (46,67%) were more than 50 years of age. 
From the last level of education, most patients 
graduated from high school, comprising 11 patients 
(36,67%) followed by primary school of 8 patients 
(26,67%). The mean body mass index was 26,08 ± 
2,86; from which 46,67% were overweight and 10% 
with obesity.
Urinary tract stone disease is common in 
productive age group, but this figure will be balanced 
in women after reaching the age of menopause, 
presumably because of hormonal influences in 
which estrogen is protective. This study revealed 
almost balanced figure because majority of the 
samples aged over 50 years. A total of 23 patients had 
performed treatment, in which 12 patients performed 
PCNL and 11 patients performed open surgery with 
residual stones less than 20 mm and ESWL was 
performed once.
Urinary tract stone disease is more frequent 
in men than in women, in which men 2 to 3 times 
more likely to suffer from the disease. Presumably 
this is related to an increase in serum testosterone 
levels, which leads to increased endogenous 
production of oxalate. In women and children, serum 
testosterone levels is low, so the risk of stone is also 
2low.
From the analysis stones, we found 
components of calcium stone of 33,48% and oxalate 
of 38,47% with calcium oxalate stone composition 
of 61,94%. It was not much different from a 
retrospective study by Wibisono (2011) who 
obtained the composition of calcium oxalate stones 
11by 87,67%.
Hypercalciuria (calcium excretion > 250 
mg/24 hours) was found in 30-60% of the patients 
with kidney stones, and about 15-20% were found 
with hyperuricosuria (uric acid excretion > 600 
mg/24 hours). In patients with kidney stones, either 
the first or recurrent, metabolic evaluation is 
necessary. Examination of 24-hour urine excretion is 
also reasonably cost-saving. This is important 
because the risk of first time stone recurrence in the 
patients can reach 50% within 5 years. In this study 
no dietary intervention was given, and all samples 
revealed hypercalciuria urinary calcium excretion of 
more than 200 mg/day. Approximately 10% of 
patients with calcium stones had hyperuricosuria. 
Hypercalciuria and hyperuricosuria are the risk 
factors for the onset of metabolic stone and should be 
investigated further. In this study in all treatment 
groups had decreased excretion of urinary calcium 
and uric acid, but not significant (p > 0,05).
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Stone size and stone surface area are 
important factors in achieving stone clearance. In 
this study there was significant decrease in the 
diameter of the stone and the stone surface area after 
Renalof administration (p < 0,05). From the 
composition of stone samples, it was found that the 
predominant was calcium oxalate stones. In other 
words, Renalof administration is effective in patients 
with calcium oxalate stones.
Phytotherapy with plant medicine is widely 
used and accepted as an alternative treatment in 
primary prevention level. In general, herbal 
medicine for urinary tract stone works through anti-
inflammatory effects, diuretic properties, litholytic, 
anti-microbial and spasmolitic.
Rock fragments of 4 mm was expected to 
come out spontaneously without the need for 
interventions, so that it is defined as clinically 
13insignificant residual fragments.  The problem will 
arise how long the spontaneous expulsion is reached. 
Because these fragments are fixed, it will be 
potential to grow and become clinically significant. 
Osman et al (2005) followed-up 173 CIRF patients 
for 5 years after ESWL. They had residual stones 
after ESWL up to 3 months in 24-36% of cases, and 
13re-growth was found at 21,4% of patients.  
Buchholz et al reported the low re-growth rate (2%) 
at follow-up for 2,5 years, while Kaitan et al reported 
14a greater number (59%) at follow-up of 15 months.  
In his research Osman and Knoll obtained stone 
13clearance of 98% in the first 12 weeks.  Such 
inconsistent figures are probably because residual 
stone also lied at lower calyx and the influence of 
gravity caused low stone clearance. Murphy et al 
recommended prophylactic therapy in lower calyx 
asymptomatic kidney stones with size > 1 cm 
because their observations showed that the 
probability of being symptomatic was 47% within 2 
15years.
CONCLUSION
The administration of Renalof® can be used 
as a complement, not a substitute for treatment in 
patients with kidney stone sized 2 cm.
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